US20030087789A1 - Emulsion containing a plant extract, method for producing said emulsion and for obtaining a plant extract - Google Patents
Emulsion containing a plant extract, method for producing said emulsion and for obtaining a plant extract Download PDFInfo
- Publication number
- US20030087789A1 US20030087789A1 US10/239,929 US23992902A US2003087789A1 US 20030087789 A1 US20030087789 A1 US 20030087789A1 US 23992902 A US23992902 A US 23992902A US 2003087789 A1 US2003087789 A1 US 2003087789A1
- Authority
- US
- United States
- Prior art keywords
- emulsion
- triterpene
- birch
- solvent
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000839 emulsion Substances 0.000 title claims abstract description 73
- 239000000419 plant extract Substances 0.000 title claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 12
- 150000003648 triterpenes Chemical class 0.000 claims abstract description 71
- 238000000034 method Methods 0.000 claims abstract description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000002537 cosmetic Substances 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 7
- 235000018185 Betula X alpestris Nutrition 0.000 claims description 72
- 235000018212 Betula X uliginosa Nutrition 0.000 claims description 72
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical group C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 claims description 57
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 claims description 55
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 claims description 54
- 230000008569 process Effects 0.000 claims description 49
- 239000002904 solvent Substances 0.000 claims description 44
- 239000007799 cork Substances 0.000 claims description 42
- 239000000284 extract Substances 0.000 claims description 42
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 28
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 27
- 238000000605 extraction Methods 0.000 claims description 24
- 239000002674 ointment Substances 0.000 claims description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 241000196324 Embryophyta Species 0.000 claims description 17
- 239000004202 carbamide Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 235000019489 Almond oil Nutrition 0.000 claims description 14
- 239000008168 almond oil Substances 0.000 claims description 14
- 235000021302 avocado oil Nutrition 0.000 claims description 14
- 239000008163 avocado oil Substances 0.000 claims description 14
- 239000006071 cream Substances 0.000 claims description 13
- 210000004761 scalp Anatomy 0.000 claims description 13
- 150000001720 carbohydrates Chemical class 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 claims description 9
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 claims description 9
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 claims description 9
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 claims description 9
- 238000009835 boiling Methods 0.000 claims description 9
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 9
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 150000004676 glycans Chemical class 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims description 7
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims description 7
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims description 7
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims description 7
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 claims description 7
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 claims description 7
- 239000003921 oil Substances 0.000 claims description 7
- 235000019198 oils Nutrition 0.000 claims description 7
- 229940100243 oleanolic acid Drugs 0.000 claims description 7
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 6
- 230000003020 moisturizing effect Effects 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 239000002562 thickening agent Substances 0.000 claims description 6
- 229920001817 Agar Polymers 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 5
- -1 hydroxy-lactone Chemical compound 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 239000002453 shampoo Substances 0.000 claims description 5
- 229940098465 tincture Drugs 0.000 claims description 5
- 241000206672 Gelidium Species 0.000 claims description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 235000010419 agar Nutrition 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 235000015110 jellies Nutrition 0.000 claims description 4
- 239000008274 jelly Substances 0.000 claims description 4
- PSZDOEIIIJFCFE-UHFFFAOYSA-N Oleanolic alcohol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C)(C)CC5C4=CCC3C21C PSZDOEIIIJFCFE-UHFFFAOYSA-N 0.000 claims description 3
- 238000010924 continuous production Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- PSZDOEIIIJFCFE-OSQDELBUSA-N erythrodiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C PSZDOEIIIJFCFE-OSQDELBUSA-N 0.000 claims description 3
- HTZRWCSRPTWJCT-UHFFFAOYSA-N erythrodiol Natural products CC1(C)CCC2(CO)CCC3C(CCC4C3(C)CCC5C(C)(C)C(O)CCC45C)C2C1 HTZRWCSRPTWJCT-UHFFFAOYSA-N 0.000 claims description 3
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 2
- IBPVZXPSTLXWCG-UHFFFAOYSA-N 22-hydroxydocosanoic acid Chemical compound OCCCCCCCCCCCCCCCCCCCCCC(O)=O IBPVZXPSTLXWCG-UHFFFAOYSA-N 0.000 claims description 2
- BZNIIOGSANMIET-JEKRXEKZSA-N Allobetulin Natural products O[C@@H]1C(C)(C)[C@H]2[C@](C)([C@@H]3[C@](C)([C@@]4(C)[C@@H]([C@H]5[C@H]6C(C)(C)CC[C@]5(CO6)CC4)CC3)CC2)CC1 BZNIIOGSANMIET-JEKRXEKZSA-N 0.000 claims description 2
- 206010027146 Melanoderma Diseases 0.000 claims description 2
- 241000209295 Melanoderma Species 0.000 claims description 2
- 208000006994 Precancerous Conditions Diseases 0.000 claims description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 2
- BZNIIOGSANMIET-UHFFFAOYSA-N allobetuline Natural products CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3)(C)C2CCC1C1C2OCC13CCC2(C)C BZNIIOGSANMIET-UHFFFAOYSA-N 0.000 claims description 2
- BZNIIOGSANMIET-HWNNWUPFSA-N allobetulinol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]([C@]1(C)CC3)(C)[C@@H]2CC[C@@H]1[C@H]1[C@H]2OC[C@]13CCC2(C)C BZNIIOGSANMIET-HWNNWUPFSA-N 0.000 claims description 2
- FSLPMRQHCOLESF-UHFFFAOYSA-N alpha-amyrenol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C FSLPMRQHCOLESF-UHFFFAOYSA-N 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- JFSHUTJDVKUMTJ-QHPUVITPSA-N beta-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C JFSHUTJDVKUMTJ-QHPUVITPSA-N 0.000 claims description 2
- QQFMRPIKDLHLKB-UHFFFAOYSA-N beta-amyrin Natural products CC1C2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C)CCC1(C)C QQFMRPIKDLHLKB-UHFFFAOYSA-N 0.000 claims description 2
- PDNLMONKODEGSE-UHFFFAOYSA-N beta-amyrin acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC23C)C1(C)C PDNLMONKODEGSE-UHFFFAOYSA-N 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 230000001804 emulsifying effect Effects 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 2
- 229940096998 ursolic acid Drugs 0.000 claims description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- 239000000470 constituent Substances 0.000 abstract description 2
- 230000037396 body weight Effects 0.000 description 40
- 241001465754 Metazoa Species 0.000 description 29
- 238000012360 testing method Methods 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 18
- 235000013877 carbamide Nutrition 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 238000007912 intraperitoneal administration Methods 0.000 description 11
- 235000014633 carbohydrates Nutrition 0.000 description 10
- 238000003745 diagnosis Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 231100000456 subacute toxicity Toxicity 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 241000219429 Betula Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 201000009053 Neurodermatitis Diseases 0.000 description 6
- 206010070863 Toxicity to various agents Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000000859 sublimation Methods 0.000 description 6
- 235000003932 Betula Nutrition 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 230000008022 sublimation Effects 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 4
- 101000809436 Candida albicans Sterol O-acyltransferase 2 Proteins 0.000 description 4
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 4
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 4
- 101000677891 Homo sapiens Iron-sulfur clusters transporter ABCB7, mitochondrial Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102100021504 Iron-sulfur clusters transporter ABCB7, mitochondrial Human genes 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 231100000403 acute toxicity Toxicity 0.000 description 4
- 230000007059 acute toxicity Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229960004544 cortisone Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 238000004817 gas chromatography Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 231100000820 toxicity test Toxicity 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- 235000009109 Betula pendula Nutrition 0.000 description 3
- 238000006027 Birch reduction reaction Methods 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000001329 hyperkeratotic effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 231100000225 lethality Toxicity 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000013557 residual solvent Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000007666 subchronic toxicity Effects 0.000 description 3
- 231100000195 subchronic toxicity Toxicity 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- WZHHYIOUKQNLQM-UHFFFAOYSA-N 3,4,5,6-tetrachlorophthalic acid Chemical class OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C(O)=O WZHHYIOUKQNLQM-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000018720 Betula occidentalis Nutrition 0.000 description 2
- 241000259168 Betula occidentalis Species 0.000 description 2
- 241000219430 Betula pendula Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NKMDIWKRKQFYPH-UHFFFAOYSA-N Lupan Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(C)C)C5C4CCC3C21C NKMDIWKRKQFYPH-UHFFFAOYSA-N 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 244000025272 Persea americana Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000206572 Rhodophyta Species 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- MHAVMNJPXLZEIG-CNRMHUMKSA-N (1r,3as,5ar,5br,7ar,11ar,11br,13ar,13br)-5a,5b,8,8,11a-pentamethyl-9-oxo-1-prop-1-en-2-yl-2,3,4,5,6,7,7a,10,11,11b,12,13,13a,13b-tetradecahydro-1h-cyclopenta[a]chrysene-3a-carbaldehyde Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MHAVMNJPXLZEIG-CNRMHUMKSA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- 244000274847 Betula papyrifera Species 0.000 description 1
- 235000009113 Betula papyrifera Nutrition 0.000 description 1
- 235000010928 Betula populifolia Nutrition 0.000 description 1
- 235000002992 Betula pubescens Nutrition 0.000 description 1
- SLJTWDNVZKIDAU-SVAFSPIFSA-N Betulonic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C SLJTWDNVZKIDAU-SVAFSPIFSA-N 0.000 description 1
- SLJTWDNVZKIDAU-CKURCAGRSA-N Betulonic acid Natural products CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@@H](CC[C@@H]4[C@@]5(C)CCC(=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O SLJTWDNVZKIDAU-CKURCAGRSA-N 0.000 description 1
- 101100326684 Caenorhabditis elegans tra-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 241001226745 Diospyros leucomelas Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000219427 Fagales Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 235000009072 Mesembryanthemum Nutrition 0.000 description 1
- 241000219480 Mesembryanthemum Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920001131 Pulp (paper) Polymers 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- ZNUAKACHFYTNFX-UHFFFAOYSA-N Wallichenol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C(=C)CO)CCC3(C)CCC21C ZNUAKACHFYTNFX-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- MHAVMNJPXLZEIG-UHFFFAOYSA-N betulinic aldehyde Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(C=O)CCC(C(=C)C)C5C4CCC3C21C MHAVMNJPXLZEIG-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000006253 efflorescence Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 231100000916 relative toxicity Toxicity 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229940056692 resinol Drugs 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000018040 scab formation Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 208000013460 sweaty Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000010698 whale oil Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 235000001459 whitebark Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S516/00—Colloid systems and wetting agents; subcombinations thereof; processes of
- Y10S516/905—Agent composition per se for colloid system making or stabilizing, e.g. foaming, emulsifying, dispersing, or gelling
Definitions
- the present invention concerns a process for obtaining triterpenes and/or their components as well as an emulsion, of which the aqueous and fatty phases are emulsified by a plant extract, wherein the plant extract contains at least one triterpene and/or a triterpene divertive and the emulsion further contains at least one oil and/or fat and water.
- the present invention concerns a process for producing the emulsion as well as the use of the triterpenes for production of cosmetics and pharmaceuticals.
- Betulin containing plants are widely distributed in the plant kingdom. They belong primarily to the Hamamelididae (angiosperm plants), where in one single species in the order fagales (birch relatives), and more particularly in the family of the betulaceen (birches), the content of betulin accumulates in the outer bark (review article: Hayek, E. W. et al., (1989), A Bicentennial of Betulin, Phytochemistry, 28(9), pages 2229-2242).
- the white part of the birch bark, in particular the species betula pedula, betula verrucosa and betula papyfera can contain more than 30% betulin.
- Betulin is a pentacyclic triterpene with a lupan skeleton, which is also referred to as betulinol, trochoton, birch camphor and (coryli) resinol.
- the characterizing feature of the lupan group is a ring with five carbon atoms within the pentacyclic system, which contains an ⁇ -isopentyl group in the position C-19.
- Betulin is further characterized by a high thermal stability, its melting point lies between 250 and 260° C., wherein even high values are obtained after sublimation of the re-crystallized product.
- birch bark is used for production of birch bark oil, which has also been used for treatment of rheumatism and as aroma therapy (Hansel, R. et al., (Hrsg.), (1994), Drug A-D, Springer Publishing House, Chapter Betula, pages 502-511; Hyek, E. W. supra).
- birch extracts as bath salts for treatment, particularly for sweaty feet, as well as additives to shampoos as a hair care agent is known (Nowak, G. A., (1966), Cosmetic and Medicinal Properties of the Birch, Amer. Perfumer Cosmet., 81, page 37).
- aqueous extracts from birch leaves have been employed, which contain practically no betulin.
- Betulinic acid derivates a new class of human immunodeficiency virus type 1 specific inhibitors with a new mode of action, J. Med. Chem. 39, pages 1056-1068; Hayek, E. W. et. al., supra).
- an anti-inflammatory, cortisone like effect as well as cytostatic effect upon use in vitro against various tumor cell lines of betulin and betulin derivatives has been shown (Carmen Recio, M., et. al. (1995), Investigations on the steroidal anti-inflammatory activity of triterpenoids from Diospyros leucomelas, Planta Med. 61, pages 9-12); Yasukawa, K., et. al., (1991), Sterol and triterpene derivates from plants ( . . . ), Oncogene 48, pages 72-76).
- the disadvantage of the sublimation technique is the fact that the content is obtained only with very low yield, which necessitates the use of large amounts of starting materials.
- a particular disadvantage of the sublimation technique is the simultaneous occurrence of tar-like decomposition products from other cork/bark components, which necessitates multiple re-sublimation or re-crystallization.
- betulin is relatively poorly soluble in the mentioned solvents and the extraction can only be carried out with high investment in time.
- multiple re-crystallizations are necessary.
- the best results are obtained with higher boiling carbohydrates (Eckermann, C. and Ekman, R. (1985), supra).
- Solvents in which betulin is highly soluble, such as for example pyridine and tetrohydrofuran, are generally considered to be toxins. They are dismissed on the basis of their health risk and their not insubstantial handling risks during extraction.
- a further disadvantage of the mentioned solvents is that substantial amounts of brown, undesired substances are dissolved at the same time, of which the later separation is extremely complex and costly and uneconomical. Accordingly, until today there is no efficient process for obtaining betulin from birch cork, whereby betulin can be produced in large amounts, with a high degree of purity and without using strong hazardous solvents.
- U.S. Pat. No. 5,647,976 a reaction vessel is described, which can be employed for extraction of contents with solvents with high pressure and elevated temperature.
- This reaction vessel is characterized by a lock, which makes it possible to introduce solvents in the reaction vessel and to remove them therefrom, without having to disturb the lock. In this manner contamination of the solvent is effectively prevented.
- the reaction vessel is simple to operate, so that it can be operated even by untrained personnel.
- U.S. Pat. No. 5,647,976 essentially describes the mentioned reaction vessel, however gives not direction as to how to carry out an extraction process. Besides this, it contains no indication regarding the quality and purity of the contents which have been isolated in the reaction vessel.
- a disadvantage of the process is in particular that it may be suitable for extracting soluble substances in an analytic sample, however is not or is only poorly suitable for preparative production and yielding of components in greater amounts and purity, since it is precisely in such processes that contamination of the sample leads to defects in the degree of purity of the extracted components. Further, the process as described in U.S. Pat. No. 5,785,856 as conceived is limited to the analytical realm. The document provides no indication regarding obtainable degrees of purity and the possibility for scaling up to industrial scale.
- anti-microbial effective preservatives were added to the described emulsifiers, whereby primarily benzoic acid derivatives were employed (Pasich, J., 1965), Triterpenoid emulsifiers of plant origin. V. Emulsifying properties of Betulin and certain of its esters. Farm. Polska 21, Nr. 17-18, pages 661-666).
- the present invention further addresses the task of providing a triterpene containing emulsion which contains pharmaceutically active components and at the same time is sufficiently stable for a longer period of time without the addition of preservatives. Besides this, the emulsion should be capable of preparation in a simple manner.
- the first task is solved thereby, that in the inventive process for obtaining of triterpenes from plants and/or their components the plant parts are first washed at 20° C. to 70° C. in a solvent in which the triterpenes are not soluble or only slightly soluble.
- the triterpenes are extracted with a solvent under increased pressure and elevated temperature.
- a cooling and simultaneous depressurization of the triterpene containing solution whereby the triterpenes precipitate in the solvent in extremely small particles and then more triterpene crystallizes onto these particles upon further cooling.
- they are washed following filtration at room temperature with a fresh solvent.
- the expression “washing ( . . . ) in a solvent, in which the triterpene ( . . . ) is not or is only slightly soluble” means that the solubility of the triterpene is not more than 1 g/liter.
- the extraction of the triterpene occurs with solvent under increased pressure and elevated temperature, in certain cases in the supercritical region.
- solvents for example supercritical carbon dioxide as well as carbohydrates in the supercritical region as well as liquid carbohydrates under elevated pressure or mixtures of different carbohydrates.
- step (e) Prior to washing [step (e)] it is advantageous that it is not necessary to dry the filter cake in a further process step. Thereby the process is particularly simple to carry out.
- step (e)] the washing of the triterpene [step (e)] can itself be carried out under normal conditions, thereby keeping the inventive process particularly simple and economical.
- the inventive process is carried out continuously.
- the plat material and cold solvent are conveyed through a pressure-tight tube by pumping, and washed in a counter-current at 20° C. to 70° C.
- the washed plant material is conveyed in a second, likewise pressure-tight and heatable tube or pipe and extracted in counter-current with fresh, supercritical heated or liquid solvent.
- the discharge of the wash solution and the extraction solution occurs respectively via a filter system.
- the plant parts are conveyed counter-current to the solvent flow on the basis of their different density and are discharged at the end opposite to the solvent discharge end.
- the extract solution is—with maintenance of the pressure in the extraction system—conveyed to spray nozzles via a valve system and it is only here that it is finally reduced in pressure.
- Birch bark is available in large amounts as an economical raw material in particular as waste products in the pulp industry.
- the triterpenes are obtained from birch bark, preferably from the white part of the birch bark, which is also referred to as birch cork.
- “Separated birch cork” refers to both the white outer layer when stripped by hand, which is sloughed off outwardly as cork skin by the trunk of the birches and thus lies outside of the actual bark, as well as the subsequently separated birch cork separated for example with the aid of a hammer mill and a flotation process from a total skinning.
- the triterpene is obtained in a purity of at least 80%, preferably 85%, in particular 90%, particularly preferably above 90%.
- the main component of the extracted triterpene is betulin, wherein its content is at least 80%, preferably 85%, in particular 90%, particularly preferably above 90%.
- a low boiling carbohydrate or a mixture which includes a low boiling carbohydrate since a low boiling carbohydrate can be subsequently very easily removed.
- the boiling point of the employed carbohydrate, or as the case may be the mixture preferably lies below 100° C.
- Particularly preferred is the employment of n-pentane, n-hexane or n-heptane, since all are inexpensive, do not harbor any special health hazards and are available in sufficient quantities in good quality.
- the first washing step is carried under a pressure of 1 to 300 bar, preferably 10 to 35 bar, particularly preferably about 25 bar.
- the actual extraction occurs preferably at a temperature of 50 to 200° C., preferably 140 to 160° C., particularly preferably about 150° C. and under a pressure of 1 to 300 bar, preferably 10 to 35 bar, particularly preferably about 25 bar.
- these extraction conditions large amounts of pure triterpenes, in particular pure betulin, are obtained.
- the inventive process has also been found to be of particular advantage, when the crystallization of the triterpene occurs as micro-crystallization with an average particle size of ⁇ 40 ⁇ m, in particular from 2 to 32 ⁇ m.
- a further atribute of the present invention is an emulsion, of which the aqueous and fatty phases are emulsified by a plant extract, wherein the plant extract includes at least one triterpene and/or at least one derivative of a triterpene and the emulsion further includes at least one oil and/or fat and water.
- the triterpene and/or its derivative preserves and emulsifies the emulsion. Besides this, it is pharmaceutically active. Thereby it is in particular achieved, that the emulsion contains no supplemental preservative, and thus possesses a particularly high degree of purity and a good compatibility above all with problematic applications to damaged skin.
- the plant extract is herein an extract of birch bark, preferably from the white part of the birch bark, which is referred to as birch cork.
- the plant extract contains at least one of the substances betulin, betulinic acid, betulonic acid, lupeol (lupol), erythrodiol, allobetulin, phellonic acid, hydroxy-lactone, betulonic aldehyde, ⁇ -amyrin, oleanolic acid, ursolic acid, esterified betulin and/or ⁇ -sitosterol.
- These plant constituents could be employed individually as well as mixed with each other in various combinations in the inventive emulsion.
- a particularly suitable combination is comprised of betulin>80%, betulinic acid ⁇ 10%, lupeol ⁇ 3%, oleanolic acid ⁇ 4%, erythrodiol ⁇ 4% and water ⁇ 1%.
- the emulsion preferably contains the triterpene and/or its derivative in a concentration of 2 to 10%. Depending upon the desired consistency, the proportion of the triterpene and/or its derivative can be varied in the mentioned concentration range. For the employment of a fluid lotion the emulsion exhibits for example a concentration of the triterpene and/or its derivative of 2 to 3.5%. If the emulsion is used in the form of a cream, the concentration of the triterpene and/or its derivative is preferably 3.5 and 10%.
- the oily and/or fatty component of the emulsion can be selected from any of the dermatological and cosmetic known oils and fats. Particularly suitable are animal and plant fats such as jojoba oil, peanut oil and olive oil. Particularly preferred is the use of avocado and/or almond oil.
- moisturizers and/or thickeners and solidifiers can be employed.
- moisturizers there can be employed in particular glycerin and urea or carbamide.
- concentrations of respectively 3 to 10% glycerin and/or urea or carbamide are suitable based upon the amount of the emulsion.
- thickener there can be employed, for example, polysaccharides, which are to be added in a concentration of 0.2 to 2%, preferably 0.5%, based upon the amount of the employed water. Natural polysaccharides as well as further sugar compounds and their derivatives are particularly suitable, since they do not react with the other components of the emulsion, they do not modify them and are thus chemically inert.
- the polysaccharide agar agar is preferably employed.
- Agar agar is a mixture of agarouse and agaropectin, which is obtained from red algae and has the advantage that it cannot be decomposed by most micro-organisms.
- the polysaccharide carrageenan can be employed which occurs naturally in the cell wall of red algae and certain brown algae and has the same advantages as agar agar.
- the emulsion comprises 2 to 10% extract from the white part of the birch bark, 20 to 30% avocado oil, 10 to 20% almond oil and 40 to 68% water.
- the most preferred concentrations comprise 4% extract from the white part of the birch bark, 29.3% avocado oil, 14.7% almond oil and 52% water.
- a further inventive emulsion contains 2 to 10% extract from the white part of the birch bark, 20 to 30% avocado oil, 10 to 20% almond oil, 5 to 10% moisturizing agent and 30 to 63% water.
- the most preferred is the concentration of 4% extract from the white part of the birch bark, 29.3% avocado oil, 14.7% almond oil, 5% glycerin and/or 5% urea and 42 to 47% water.
- the extract from the white part of the birch bark which is contained in all emulsions, comprises at least 80% betulin, at most 10% betulinic acid, at most 3% lupeol and at most 4% oleanolic acid.
- the emulsion on the basis of its composition and its verifiable biocompatibility, is particularly suitable as a salve base for addition of all known fragrances, cosmetics and medicinal active agents.
- a further atribute of the invention is a process for producing the inventive emulsion, wherein the process includes the following steps:
- the dispersion and homogenization preferably occurs in a homogenizing mixer since the process can be carried in particularly simple manner in this way. Further, it is possible to prepare small amounts of emulsion for individual applications.
- a moisturizing agent in particular glycerin and/or urea, or a thickener, in particular a polysaccharide.
- a further attribute of the present invention is the use of the triterpenes for manufacture of a cosmetic, preferably in the form of a salve, a lotion, a cream, a gel, a jelly, a tincture, a shampoo, a powder and/or a cosmetic (compact) powder, in particular for application upon the skin, the face or scalp or scalp and/or for inhalation.
- a cosmetic preferably in the form of a salve, a lotion, a cream, a gel, a jelly, a tincture, a shampoo, a powder and/or a cosmetic (compact) powder, in particular for application upon the skin, the face or scalp or scalp and/or for inhalation.
- the triterpenes in particular the obtained betulin, are particularly suitable for skin and head care. It relaxes and smoothes skin, reduces the water loss and induces attractiveness and blush.
- the cosmetic can be particularly employed for maintaining moisture of the skin and smoothing the skin as well as for reduction of age spots and can be employed in the case of dandruff or flaking skin.
- a further advantage is the water insolubility of the triterpenes, so that skin which is exposed to water vigorously and for prolonged periods is particularly well protected.
- the use as deodorant is particularly advantageous. Added to this is the minimization of transpiration on the basis of an effective closure of the sweat glands.
- a further attribute of the present invention is the use of the triterpenes for production of a pharmaceutical or medicinal formulation, preferably in the form of a salve, a lotion, a cream, a gel, a jelly, a tincture, a shampoo, a powder and/or a cosmetic (compact) powder, in particular for application upon the skin, the face or scalp or scalp, and/or for inhalation, particularly preferably for treatment of dermatological conditions of the skin and/or the scalp, above all for neurodermitis, psoriasis, contact eczema, melanoderma, impetigo, pre-cancerous conditions of the skin as well as for inhalation during asthmatic attacks and/or for substitution in place of glucocorticoids.
- the obtained triterpenes in particular the obtained betulin, is suitable for the therapeutic application on pre-cancerous skin.
- inventive emulsion is so well suited for the above-mentioned applications because the extract from the white part of the birch bark includes no mutagenic characteristics. Topical toxicity tests were likewise carried out, wherefrom no sensitizing characteristics were discovered.
- Diagnosis heavy, generalized psoriasis vulgaris
- Treatment multiple daily application of the inventive emulsion as salve upon the afflicted skin areas
- Treatment multiple daily application of the inventive emulsion as salve upon the afflicted skin areas
- Diagnosis neurodermitis, hyperkeratotic, prematurely aged, chapped-shriveled skin
- Treatment multiple daily applications of the inventive emulsion as salve upon the afflicted skin areas
- Diagnosis neurodermitis, hyperkeratotic, prematurely aged, chapped-shriveled skin
- Treatment multiple daily applications of the inventive emulsion as salve upon the afflicted skin areas
- Diagnosis neurodermitis, hyperkeratotic, prematurely aged, chapped-shriveled skin
- Treatment multiple daily applications of the inventive emulsion as salve upon the afflicted skin areas
- Treatment multiple daily application of the inventive emulsion as salve upon the afflicted skin areas
- Treatment multiple daily application of the inventive emulsion as salve upon the afflicted skin areas
- Treatment multiple daily application of the inventive emulsion as salve upon the afflicted skin areas
- Diagnosis dry, itching, easily infected scabbing eczema
- Treatment multiple daily application of the inventive emulsion as salve upon the afflicted skin areas
- the birch cork was delivered by:
- Kaukas The “wood pulp company Kaukas” (UPM-Kymmene Lappeenranta, Finland). Kaukas separates the bark mechanically from the birch wood and the cork is also mechanically removed from the inner bark.
- a first step the mechanically separated and the hand cut cork is analyzed regarding its identity.
- the cork is microscopically examined, whereby multiple individual cork layers and lenticular cells, which are typical for birch, can be seen.
- the extractable amount of triterpenes with n-hexane at 140 to 160° C. under increasing pressure is examined.
- the extractable amount of triterpene with the main component betulin exceeded 10%, since such amounts occur only in the cork of birches with white bark.
- the cork was ground in a cutting mill (produced by the company Retsch) and suctioned off out of the machine through a sieve with a pore size of 1 mm diameter. For the further extraction, only particles with a particle size ⁇ 1 mm were employed.
- Betulin at least 80%
- Betulinic acid at most 10%
- the overview shows a typical gas chromatogram with values of 84 to 86% betulin, 4 to 5% betulinic acid, approximately 1% lupeol and approximately 1% oleanolic acid.
- the amount of the solvent n-hexane remaining must be ⁇ 7,725 mg/kg extract, while a cream containing 4% birch cork extract may not contain more than 290 mg/kg n-hexane.
- Typical values comprise 1,500 mg/kg n-hexane in dried extract, which corresponds to approximately 60 mg/kg in the birch cream.
- Each charge was checked according to the European requirements with respect to the acid value ( ⁇ 5) and the peroxide number ( ⁇ 15) by means of a standardized process.
- the content of birch cork extract was analyzed using GC. Further, an examination was made regarding microbes ( ⁇ 100/g); besides this, no pathological microbes may be contained.
- the inventive formulation is set forth in Table 1 (Tab. 1). They were comprised of the following composition: TAB. 1 Composition of the Formulation Active Component in all Extract from Birch cork Formulations 40 ⁇ 4 mg/g Cream (4%) Formulation Ingredient in % Birch Cream A 29.3 avocado oil 14.7 Almond oil 52 Water Birch Cream G 29.3 avocado oil 14.7 Almond oil 5 Glycerin 47 Water Birch Cream H 29.3 avocado oil 14.7 Almond oil 5 Urea 47 Water
- All three formations contained the same amount of the active component (birch cork extract) as well as avocado and almond oil. They differed essentially with respect to the component urea (only in birch cream H) as well as glycerin (only in birch cream G), birch cream A is free of these components.
- the birch cream was centrifuged at 500 ⁇ g and was found to be stable therein.
- the acute toxicity of the birch cork extract was determined by intra-peritoneal and subcutaneous administration to mice and rats.
- the lethality was determined 14 days after the administration of an individual dose for determination of the average lethal dose LD 50 . At the same time the animals were observed in order to detect symptoms of toxicity. As such there were considered local and systemic intolerance reactions as well as changes in the body weight. The animals were sacrificed at the end of the experiment and examined microscopically. The acute toxicity test followed EC guidelines L 383 A: B1.
- Chemicals are classified on the basis of their relative toxicity. They are characterized as toxic when the LD 50 valve us between 50 and 500 mg/kg body weight. With a LD 50 value of 5000 to 15000 mg/kg body weight there is the presumption of practically no toxicity.
- the LD 50 value is >2000 mg/kg body weight, and is very likely also >5000 mg/kg body weight, since even with the high value of 2000 mg/kg body weight no toxic symptoms were observed.
- the birch cork extract can be characterized as non-toxic.
- Birch cork extract (charge-number: Bet. 009) was administered to experimental rats (Sprague-Dawley/Crl: CD® BR) by means of intraperitoneal injection over 14 days within the framework of a subacute toxicity test.
- the test protocol is summarized in Table 4 (Tab. 4). TAB.
- Dogs (Beagle), i.p.
- a subacute toxicity was carried out over a period of two weeks with Beagles as dose-determining experiment, over 4 weeks as subchronic toxicity test.
- the birch cork extract (Batch No.: Bet. 009) was administered intra-peritoneal with sesame oil as the carrier.
- the results are summarized in Table 8 (Tab. 8).
- TAB. 9 Subacute toxicity test in dogs (beagles), i.p. No effect: ⁇ 50 mg/kg body weight/day during the MTD time
- Lethal dose 500 mg/kg body weight/day
- Toxic indication during the fixed dose time (100, 300 mg/kg body weight/day)
- Reduced body weight Reduced food uptake Change in hematopoetic and biochemical parameters Heavy stomach fur inflammation in 3 of 8 animals* )
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Pulmonology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- General Preparation And Processing Of Foods (AREA)
- Medicinal Preparation (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Extraction Or Liquid Replacement (AREA)
- Seasonings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Fats And Perfumes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
- The present invention concerns a process for obtaining triterpenes and/or their components as well as an emulsion, of which the aqueous and fatty phases are emulsified by a plant extract, wherein the plant extract contains at least one triterpene and/or a triterpene divertive and the emulsion further contains at least one oil and/or fat and water. Besides this, the present invention concerns a process for producing the emulsion as well as the use of the triterpenes for production of cosmetics and pharmaceuticals.
- Natural ingredients, fragrances or flavors and active substances have for a long time been isolated, using various extraction techniques, from whole plants and their parts, such as leaves, roots, fruits or bark. As one of the first natural substances, betulin (birch camphor), the substance which imparts to birch bark its white color, was extracted from plant material in the year 1788 (Lowitz, M., Chemische Analysen, Hrsg. Crell, L., Vol. 2, page 312). Subsequent to this first isolation there followed scientific studies, including elementary analysis of betulin, which were published by U. Hausmann 1876 (Hausmann, U., Annalen der Chemis, 182, page 368).
- Betulin containing plants are widely distributed in the plant kingdom. They belong primarily to the Hamamelididae (angiosperm plants), where in one single species in the order fagales (birch relatives), and more particularly in the family of the betulaceen (birches), the content of betulin accumulates in the outer bark (review article: Hayek, E. W. et al., (1989), A Bicentennial of Betulin, Phytochemistry, 28(9), pages 2229-2242). The white part of the birch bark, in particular the speciesbetula pedula, betula verrucosa and betula papyfera can contain more than 30% betulin. More precise research was published by Rainer Ekman in the year 1983, according to which 21-40% triterpene, or 16.7-34% betulin, were extracted from the dry outer bark of betula verrucosa (Ekman, R. (1983a), Holzforschung, 37, page 205-211). The inner bark, in comparison, contained only traces of triterpenes, in the realm of approximately 0.37-0.43% (Eckman, R. (1983b), Finn. Chem. Letters, page 162).
- Betulin is a pentacyclic triterpene with a lupan skeleton, which is also referred to as betulinol, trochoton, birch camphor and (coryli) resinol. The characterizing feature of the lupan group is a ring with five carbon atoms within the pentacyclic system, which contains an α-isopentyl group in the position C-19. Betulin is further characterized by a high thermal stability, its melting point lies between 250 and 260° C., wherein even high values are obtained after sublimation of the re-crystallized product. Its molecular weight is 442.7, it is soluble in pyridine and tetrahydrofuran, however only slightly soluble in dichloromethane, chloroform and cold organic solvents, wherein its solubility however significantly increases with increasing temperature. In water and cold petroleum ether [carbohydrate with 5 to 8 C-atoms (C5-C8 CH)] betulin is practically insoluble. Besides this, kinetic research has shown low reactivity of the hydroxy group of betulin (review article: Jääskeläinen, P. (1981), Paperi ja Puu—Papper och Trä 10, pages 599-603).
- Already in the year 1899 J. Wheeler demonstrated the antiseptic characteristics of betulin, it is thus used for sterilization of bandages and adhesive medical plaster (Wheeler, J. 1899), Pharm. J., The Production of Betulin by Sublimation, 494, Ref. Chem. Centr. 1900 I, page 353). In natural medicine and folk remedies products from cooking birch bark were and are still employed, wherein however only the inner part is used, which contains only residue of the white birch bark and, due to its low solubility, most likely contains no betulin, since the content of betulin in the inner bark is less than 0.5% and betulin is insoluble in water or water-alcohol mixtures (up to 60% alcohol) (Ekman, R. (1983b), supra).
- The thus obtained product of boiling is used for treatment of hot flashes, water craving, gout and for skin diseases, as well as a tincture for bandages for abscesses. Further, birch bark is used for production of birch bark oil, which has also been used for treatment of rheumatism and as aroma therapy (Hansel, R. et al., (Hrsg.), (1994), Drug A-D, Springer Publishing House, Chapter Betula, pages 502-511; Hyek, E. W. supra). Besides this, the use of birch extracts as bath salts for treatment, particularly for sweaty feet, as well as additives to shampoos as a hair care agent is known (Nowak, G. A., (1966), Cosmetic and Medicinal Properties of the Birch, Amer. Perfumer Cosmet., 81, page 37). Here, however, only aqueous extracts from birch leaves have been employed, which contain practically no betulin.
- Newer research suggests a medicinal effect of betulin and betulin derivatives. In animal tests betulinic acid inhibited the replication of retroviruses, in particular the human immune deficiency virus (HIV1). The published bacteriostatic and bactericidal effect of betulin against intestinalEscherichia coli, Salmonella typhi, Shigella flexneri and Staphylococcus aureus suggest a broader medicinal application (Chen Sun, J. et. al., (1998), Anti-AIDS Agents, 32, Synthesis and anti-HIV activity of Betulin derivates, Bioorganic & Medical Chemistry Letters 8, pages. 1267-1272; Evers, M. et. al., (1996), Betulinic acid derivates: a new class of human immunodeficiency virus type 1 specific inhibitors with a new mode of action, J. Med. Chem. 39, pages 1056-1068; Hayek, E. W. et. al., supra). Further an anti-inflammatory, cortisone like effect as well as cytostatic effect upon use in vitro against various tumor cell lines of betulin and betulin derivatives has been shown (Carmen Recio, M., et. al. (1995), Investigations on the steroidal anti-inflammatory activity of triterpenoids from Diospyros leucomelas, Planta Med. 61, pages 9-12); Yasukawa, K., et. al., (1991), Sterol and triterpene derivates from plants ( . . . ), Oncogene 48, pages 72-76).
- For obtaining betulin from birch bark, in particular from birch cork, one could consider using, besides sublimation (Lowitz, M., supra), above all extraction in broiling solvents. As solvent there are employed mainly alcohol and chlorinated carbohydrates (Ukkonen, K. and Era, V., (1979), Kemia-Kemi 5, pages 217-220; Ekman, R. (1983a), supra; Eckermann, C. and Ekman, R., (1985), Paperi ja Puu—Papper och Tra 3, pages 100-106; O'Connell, M. M. et al., (1988), Phytochemistry 7, pages 2175-2176; Hua, Y. et al., (1991), Journal of Wood Chemistry and Technology 11(4), pages 503-516).
- The disadvantage of the sublimation technique is the fact that the content is obtained only with very low yield, which necessitates the use of large amounts of starting materials. Besides this, a particular disadvantage of the sublimation technique is the simultaneous occurrence of tar-like decomposition products from other cork/bark components, which necessitates multiple re-sublimation or re-crystallization. With the use of the extraction method it is particularly disadvantageous that betulin is relatively poorly soluble in the mentioned solvents and the extraction can only be carried out with high investment in time. Here also multiple re-crystallizations are necessary. The best results are obtained with higher boiling carbohydrates (Eckermann, C. and Ekman, R. (1985), supra). These are however particularly disadvantageous for use in cosmetics and medicines due to the unavoidable residual solvents in the product.
- Solvents, in which betulin is highly soluble, such as for example pyridine and tetrohydrofuran, are generally considered to be toxins. They are dismissed on the basis of their health risk and their not insubstantial handling risks during extraction. A further disadvantage of the mentioned solvents is that substantial amounts of brown, undesired substances are dissolved at the same time, of which the later separation is extremely complex and costly and uneconomical. Accordingly, until today there is no efficient process for obtaining betulin from birch cork, whereby betulin can be produced in large amounts, with a high degree of purity and without using strong hazardous solvents.
- In the state of the art, further processes are know for extraction of lipophilic natural substances using high pressure and high temperature. For example, in U.S. Pat. No. 5,843,311 a process is described for isolation of organic materials using organic solvents. With the aid of this analytic process, which is used on a small scale, samples can be tested for contaminants, impurities or additives. This analytic process is used primarily for monitoring in the nutrition and health agent industry, in the pharmaceutical industry and in the analysis of ground samples. A disadvantage of this process is its limitation to the small analytical scale.
- In U.S. Pat. No. 5,647,976 a reaction vessel is described, which can be employed for extraction of contents with solvents with high pressure and elevated temperature. This reaction vessel is characterized by a lock, which makes it possible to introduce solvents in the reaction vessel and to remove them therefrom, without having to disturb the lock. In this manner contamination of the solvent is effectively prevented. In addition, the reaction vessel is simple to operate, so that it can be operated even by untrained personnel. U.S. Pat. No. 5,647,976 essentially describes the mentioned reaction vessel, however gives not direction as to how to carry out an extraction process. Besides this, it contains no indication regarding the quality and purity of the contents which have been isolated in the reaction vessel. U.S. Pat. No. 5,660,727 discloses the use of the reaction vessel from U.S. Pat. No. 5,647,976 in an automatic rotation unit, which enables the simultaneous analysis of multiple samples. The volume of each reaction vessel which can be introduced into the reaction unit lies between 10 and 30 ml. Thus, these devices find application in the analytic realm, and they are not suitable for employment in a large-scale framework.
- In U.S. Pat. No. 5,785,856, which is a divisional of U.S. Pat. No. 5,660,727, there is described, besides the rotation device, also a process for extraction of components using solvents. The process is carried out under increased pressure and elevated temperature. For this, the reaction vessel is filled with the sample material to be analyzed, and the rotation unit is activated and automatically has solvent added to it. Subsequently the pressure and the temperature are increased to predetermined values. After successful extraction the solvent is diverted to a receptacle container. The reaction vessel inclusive of the supply and removal lines can be rinsed with an inert gas such as for example nitrogen for cleaning. A disadvantage of the process is in particular that it may be suitable for extracting soluble substances in an analytic sample, however is not or is only poorly suitable for preparative production and yielding of components in greater amounts and purity, since it is precisely in such processes that contamination of the sample leads to defects in the degree of purity of the extracted components. Further, the process as described in U.S. Pat. No. 5,785,856 as conceived is limited to the analytical realm. The document provides no indication regarding obtainable degrees of purity and the possibility for scaling up to industrial scale.
- All processes described in the state of the art work discontinuously, that is, a predetermined amount is respectively extracted in a vessel to be filled and subsequently emptied. Until now no continuous process has been made available, for continuously supplying plant materials and fresh solvent, extracting in a counter-current process, and simultaneously withdrawing the extract-saturated solvent as well the completely extracted plant material.
- Besides this, in the state of the art various attempts have already been undertaken to modify the surface or scalp active characteristics of betulin, in order to produce technically useful products. So, for example, Pasich already carried out experiments in the 60's with betulin and its esters such as the succianates, phthalates and tetrachlorophthalates as emulsifiers for white vaseline, whale oil and peanut oil, and came to the conclusion that betulin, with respect to its emulsification properties, that its, ability to connect aqueous and oily components with each other, was comparable with known technical or industrial emulsifiers. His betulin containing emulsifiers were however less stable. He employed re-crystallized betulin and achieved no satisfactory stability of the emulsions. Preferred were the phthalate and tetrachlorophthalate, which were produced with the objective of better water solubility. Oily layers separated out of the emulsions after a short time, which indicated its insufficient stability. Besides this, anti-microbial effective preservatives were added to the described emulsifiers, whereby primarily benzoic acid derivatives were employed (Pasich, J., 1965), Triterpenoid emulsifiers of plant origin. V. Emulsifying properties of Betulin and certain of its esters. Farm. Polska 21, Nr. 17-18, pages 661-666).
- It is however precisely the addition of preservatives, which for their part can induce allergenic and toxic effects, which frequently destroy the positive therapeutic effect of the betulin, particularly on damaged skin, so that the preparations of betulin containing emulsions described in the literature cannot be used, or be used only to a limited extent, in modern skin care.
- These disadvantages in the state of the art have resulted in no mentionable technical preparation, use or employment of the triterpenes contained in birch cork, in particular the betulin contained therein in large amounts, despite the large amounts of birch bark available today as waste product in wood harvesting.
- The amounts of presently non-utilized betulin are enormous. Even considering only one single pulp factory in Finland (UPM Kymmene, Lappeenranta, Finland) an extractable amount of approximately 4,000 to 5,000 tons of betulin per year are incinerated as waste. In Sweden, Finland, Russia and Canada a large number of pulp factories of this size are operational. An economic utilization of this replenishable natural resource stands and falls with the economic feisability of the extraction process, which until now has not been described, and which is made available for the first time by the present invention.
- The present invention has as a first objective the provision of a process which, with the use of tenable solvents, makes possible the obtaining of large amounts of triterpenes with high purity in either the batch process or a continuous process. Besides this, this process should provide the possibility of utilizing the birch bark that is presently a waste product in the pulp industry. Besides this, the process should be simple, cost effective and rapidly completed. Further, it should be guaranteed that the amount of residual solvent in the extract falls within the guidelines of the European pharmaceutical handbook, and in particular the “Guideline for Residual Solvents”: ICH Q3C-Impurities (ICH=International Conference on Harmonization of technical requirements for registration of pharmaceuticals for human use). The present invention further addresses the task of providing a triterpene containing emulsion which contains pharmaceutically active components and at the same time is sufficiently stable for a longer period of time without the addition of preservatives. Besides this, the emulsion should be capable of preparation in a simple manner.
- The first task is solved thereby, that in the inventive process for obtaining of triterpenes from plants and/or their components the plant parts are first washed at 20° C. to 70° C. in a solvent in which the triterpenes are not soluble or only slightly soluble.
- Subsequently the triterpenes are extracted with a solvent under increased pressure and elevated temperature. Next, there is carried out a cooling and simultaneous depressurization of the triterpene containing solution, whereby the triterpenes precipitate in the solvent in extremely small particles and then more triterpene crystallizes onto these particles upon further cooling. In order to further increase the purity of the triterpenes, they are washed following filtration at room temperature with a fresh solvent. By this process it is in particular achieved, that triterpenes can be obtained in simple manner on an industrial scale.
- In the framework of the present invention the expression “washing ( . . . ) in a solvent, in which the triterpene ( . . . ) is not or is only slightly soluble” means that the solubility of the triterpene is not more than 1 g/liter. By this first washing step the easily soluble impurities are removed in advantageous manner.
- The extraction of the triterpene occurs with solvent under increased pressure and elevated temperature, in certain cases in the supercritical region. Therein there can be used as solvents for example supercritical carbon dioxide as well as carbohydrates in the supercritical region as well as liquid carbohydrates under elevated pressure or mixtures of different carbohydrates.
- Prior to washing [step (e)] it is advantageous that it is not necessary to dry the filter cake in a further process step. Thereby the process is particularly simple to carry out.
- Besides this, the washing of the triterpene [step (e)] can itself be carried out under normal conditions, thereby keeping the inventive process particularly simple and economical.
- In a particularly preferred embodiment the inventive process is carried out continuously. For this, the plat material and cold solvent are conveyed through a pressure-tight tube by pumping, and washed in a counter-current at 20° C. to 70° C. By a second pump system the washed plant material is conveyed in a second, likewise pressure-tight and heatable tube or pipe and extracted in counter-current with fresh, supercritical heated or liquid solvent. The discharge of the wash solution and the extraction solution occurs respectively via a filter system. The plant parts are conveyed counter-current to the solvent flow on the basis of their different density and are discharged at the end opposite to the solvent discharge end. The extract solution is—with maintenance of the pressure in the extraction system—conveyed to spray nozzles via a valve system and it is only here that it is finally reduced in pressure.
- Birch bark is available in large amounts as an economical raw material in particular as waste products in the pulp industry. In a preferred embodiment of the present invention the triterpenes are obtained from birch bark, preferably from the white part of the birch bark, which is also referred to as birch cork.
- “Separated birch cork” refers to both the white outer layer when stripped by hand, which is sloughed off outwardly as cork skin by the trunk of the birches and thus lies outside of the actual bark, as well as the subsequently separated birch cork separated for example with the aid of a hammer mill and a flotation process from a total skinning.
- In a particularly preferred embodiment the triterpene is obtained in a purity of at least 80%, preferably 85%, in particular 90%, particularly preferably above 90%.
- In a further illustrative embodiment the main component of the extracted triterpene is betulin, wherein its content is at least 80%, preferably 85%, in particular 90%, particularly preferably above 90%.
- Further, it is advantageous to use the same solvent for the first washing step, the actual extraction and the subsequent washing step. In this manner the best purity values can be achieved. Beyond this, it is particularly simple to carry out the process when using only one single solvent.
- As solvent there is particularly suitable a low boiling carbohydrate or a mixture which includes a low boiling carbohydrate, since a low boiling carbohydrate can be subsequently very easily removed. The boiling point of the employed carbohydrate, or as the case may be the mixture, preferably lies below 100° C. Particularly preferred is the employment of n-pentane, n-hexane or n-heptane, since all are inexpensive, do not harbor any special health hazards and are available in sufficient quantities in good quality.
- It has been found to be of particular advantage to employ for the first washing step that solvent which was collected as filtrate after the main extraction. In this manner large amounts of impurities are removed from the starting material in advance, without having to expend any additional fresh solvent. These contaminations or impurities would have had a negative influence on the degree of purity following extraction. In order to further increase the degree of purity, the extracted components can be subsequently post washed with fresh solvent.
- In a preferred embodiment the first washing step is carried under a pressure of 1 to 300 bar, preferably 10 to 35 bar, particularly preferably about 25 bar. The actual extraction occurs preferably at a temperature of 50 to 200° C., preferably 140 to 160° C., particularly preferably about 150° C. and under a pressure of 1 to 300 bar, preferably 10 to 35 bar, particularly preferably about 25 bar. In these extraction conditions large amounts of pure triterpenes, in particular pure betulin, are obtained.
- The inventive process has also been found to be of particular advantage, when the crystallization of the triterpene occurs as micro-crystallization with an average particle size of <40 μm, in particular from 2 to 32 μm.
- A further atribute of the present invention is an emulsion, of which the aqueous and fatty phases are emulsified by a plant extract, wherein the plant extract includes at least one triterpene and/or at least one derivative of a triterpene and the emulsion further includes at least one oil and/or fat and water.
- The triterpene and/or its derivative preserves and emulsifies the emulsion. Besides this, it is pharmaceutically active. Thereby it is in particular achieved, that the emulsion contains no supplemental preservative, and thus possesses a particularly high degree of purity and a good compatibility above all with problematic applications to damaged skin.
- The plant extract is herein an extract of birch bark, preferably from the white part of the birch bark, which is referred to as birch cork.
- In a further embodiment the plant extract contains at least one of the substances betulin, betulinic acid, betulonic acid, lupeol (lupol), erythrodiol, allobetulin, phellonic acid, hydroxy-lactone, betulonic aldehyde, β-amyrin, oleanolic acid, ursolic acid, esterified betulin and/or β-sitosterol. These plant constituents could be employed individually as well as mixed with each other in various combinations in the inventive emulsion. A particularly suitable combination is comprised of betulin>80%, betulinic acid<10%, lupeol<3%, oleanolic acid<4%, erythrodiol<4% and water<1%.
- The emulsion preferably contains the triterpene and/or its derivative in a concentration of 2 to 10%. Depending upon the desired consistency, the proportion of the triterpene and/or its derivative can be varied in the mentioned concentration range. For the employment of a fluid lotion the emulsion exhibits for example a concentration of the triterpene and/or its derivative of 2 to 3.5%. If the emulsion is used in the form of a cream, the concentration of the triterpene and/or its derivative is preferably 3.5 and 10%.
- The oily and/or fatty component of the emulsion can be selected from any of the dermatological and cosmetic known oils and fats. Particularly suitable are animal and plant fats such as jojoba oil, peanut oil and olive oil. Particularly preferred is the use of avocado and/or almond oil.
- In order to regulate the consistency of the inventive emulsion, conventional moisturizers and/or thickeners and solidifiers can be employed. As moisturizers there can be employed in particular glycerin and urea or carbamide. Herein above all concentrations of respectively 3 to 10% glycerin and/or urea or carbamide are suitable based upon the amount of the emulsion. As thickener there can be employed, for example, polysaccharides, which are to be added in a concentration of 0.2 to 2%, preferably 0.5%, based upon the amount of the employed water. Natural polysaccharides as well as further sugar compounds and their derivatives are particularly suitable, since they do not react with the other components of the emulsion, they do not modify them and are thus chemically inert.
- Thus the polysaccharide agar agar is preferably employed. Agar agar is a mixture of agarouse and agaropectin, which is obtained from red algae and has the advantage that it cannot be decomposed by most micro-organisms. Alternatively, the polysaccharide carrageenan can be employed which occurs naturally in the cell wall of red algae and certain brown algae and has the same advantages as agar agar.
- In a further embodiment the emulsion comprises 2 to 10% extract from the white part of the birch bark, 20 to 30% avocado oil, 10 to 20% almond oil and 40 to 68% water. The most preferred concentrations comprise 4% extract from the white part of the birch bark, 29.3% avocado oil, 14.7% almond oil and 52% water.
- A further inventive emulsion contains 2 to 10% extract from the white part of the birch bark, 20 to 30% avocado oil, 10 to 20% almond oil, 5 to 10% moisturizing agent and 30 to 63% water. Herein the most preferred is the concentration of 4% extract from the white part of the birch bark, 29.3% avocado oil, 14.7% almond oil, 5% glycerin and/or 5% urea and 42 to 47% water.
- The extract from the white part of the birch bark, which is contained in all emulsions, comprises at least 80% betulin, at most 10% betulinic acid, at most 3% lupeol and at most 4% oleanolic acid.
- The emulsion, on the basis of its composition and its verifiable biocompatibility, is particularly suitable as a salve base for addition of all known fragrances, cosmetics and medicinal active agents.
- A further atribute of the invention is a process for producing the inventive emulsion, wherein the process includes the following steps:
- (a) dispersion of triterpene in an oil and/or fat;
- (b) emulsification of water;
- (c) homogenization of the emulsion to the desired consistency.
- Herein the dispersion and homogenization preferably occurs in a homogenizing mixer since the process can be carried in particularly simple manner in this way. Further, it is possible to prepare small amounts of emulsion for individual applications.
- In a particularly preferred embodiment there is added to the water which is used during emulsification a moisturizing agent, in particular glycerin and/or urea, or a thickener, in particular a polysaccharide. Thereby a particularly creamy consistency can be achieved.
- A further attribute of the present invention is the use of the triterpenes for manufacture of a cosmetic, preferably in the form of a salve, a lotion, a cream, a gel, a jelly, a tincture, a shampoo, a powder and/or a cosmetic (compact) powder, in particular for application upon the skin, the face or scalp or scalp and/or for inhalation. On the basis of its chemical relationship to sterols the triterpenes, in particular the obtained betulin, are particularly suitable for skin and head care. It relaxes and smoothes skin, reduces the water loss and induces attractiveness and blush. Thereby the cosmetic can be particularly employed for maintaining moisture of the skin and smoothing the skin as well as for reduction of age spots and can be employed in the case of dandruff or flaking skin. A further advantage is the water insolubility of the triterpenes, so that skin which is exposed to water vigorously and for prolonged periods is particularly well protected. On the basis of the anti-bacterial effect the use as deodorant is particularly advantageous. Added to this is the minimization of transpiration on the basis of an effective closure of the sweat glands.
- A further attribute of the present invention is the use of the triterpenes for production of a pharmaceutical or medicinal formulation, preferably in the form of a salve, a lotion, a cream, a gel, a jelly, a tincture, a shampoo, a powder and/or a cosmetic (compact) powder, in particular for application upon the skin, the face or scalp or scalp, and/or for inhalation, particularly preferably for treatment of dermatological conditions of the skin and/or the scalp, above all for neurodermitis, psoriasis, contact eczema, melanoderma, impetigo, pre-cancerous conditions of the skin as well as for inhalation during asthmatic attacks and/or for substitution in place of glucocorticoids. Likewise, on the basis of their high purity, the obtained triterpenes, in particular the obtained betulin, is suitable for the therapeutic application on pre-cancerous skin.
- The inventive emulsion is so well suited for the above-mentioned applications because the extract from the white part of the birch bark includes no mutagenic characteristics. Topical toxicity tests were likewise carried out, wherefrom no sensitizing characteristics were discovered.
- The following examples serve for illustrating and imparting a better understanding of the present invention, but should in no way be considered as limitations.
- Various clinic observations of dermatological skin changes were carried out by general practice doctors as well as clinical doctors. Following the diagnosis by the doctors there occurred a treatment of the patients with the inventive emulsion, which was produced in accordance with described processes.
- Patient: male, 68 years
- Diagnosis: heavy, generalized psoriasis vulgaris
- Pre-Treatment: medium strength cortisone salve
- Application: scalp
- Treatment: multiple daily application of the inventive emulsion as salve upon the afflicted skin areas
- Results: the occurrence of psoriasis efflorescence following application of the cortisone salve was prevented by the application of the inventive emulsion
- Patient: male, 48 years
- Diagnosis: light psoriasis vulgaris
- Pre-Treatment: medium strength cortisone salve
- Application: head
- Treatment: multiple daily application of the inventive emulsion as salve upon the afflicted skin areas
- Results: healing of the approximately dollar-piece sized presternal inflamed focal areas of the infection on the head upon application of the inventive emulsion within 14 days; reinflamation of the infection (=recidivist) after cessation of application of emulsion; renewed definite improvement upon resumption of the treatment
- Patient: female, 5 months
- Diagnosis: neurodermitis, hyperkeratotic, prematurely aged, chapped-shriveled skin
- Application: body
- Treatment: multiple daily applications of the inventive emulsion as salve upon the afflicted skin areas
- Results: very noticeable improvement, excellent effectiveness with simultaneously good compatibility
- Patient: female, 10 years
- Diagnosis: neurodermitis, hyperkeratotic, prematurely aged, chapped-shriveled skin
- Application: body
- Treatment: multiple daily applications of the inventive emulsion as salve upon the afflicted skin areas
- Results: very noticeable improvement, excellent effectiveness with simultaneously good compatibility
- Patient: male, 5 months
- Diagnosis: neurodermitis, hyperkeratotic, prematurely aged, chapped-shriveled skin
- Application: body
- Treatment: multiple daily applications of the inventive emulsion as salve upon the afflicted skin areas
- Results: very noticeable improvement, excellent effectiveness with simultaneously good compatibility.
- Patient: female, 28 years
- Diagnosis: neurodermitis, neuodermitic effloresce
- Application: elbows, face or scalp, neck line
- Pre-Treatment: Dermatodoron,Stibium metallicum, salve, Top-isolon-bartel salve, mesembryanthemum salve, following application of these salves there resulted no overall improvement of the neurodermitic sites
- Treatment: multiple daily application of the inventive emulsion as salve upon the afflicted skin areas
- Results: significant reduction of the neurodermitis
- Patient: female, 78 years
- Diagnosis: seborrheic eczema
- Application: head
- Treatment: multiple daily application of the inventive emulsion as salve upon the afflicted skin areas
- Results: reduction of scab formation in the scalp area, red areas blistered somewhat slower
- Patient: female, 55 years
- Diagnosis: strong itching, dandruff, moist eczema
- Application: scalp, head
- Treatment: multiple daily application of the inventive emulsion as salve upon the afflicted skin areas
- Results: visible improvement of the treated areas
- Patient: female, 33 years
- Diagnosis: dry, itching, easily infected scabbing eczema
- Application: lower side
- Treatment: multiple daily application of the inventive emulsion as salve upon the afflicted skin areas
- Results: not yet evaluated
- Starting Material: Birch cork
- A) Description of Quality Assurance
- The birch cork was delivered by:
- 1. The “wood pulp company Kaukas” (UPM-Kymmene Lappeenranta, Finland). Kaukas separates the bark mechanically from the birch wood and the cork is also mechanically removed from the inner bark.
- 2. Co-workers, which cut the cork by hand.
- In a first step the mechanically separated and the hand cut cork is analyzed regarding its identity. For this purpose the cork is microscopically examined, whereby multiple individual cork layers and lenticular cells, which are typical for birch, can be seen. In addition the extractable amount of triterpenes with n-hexane at 140 to 160° C. under increasing pressure is examined. The extractable amount of triterpene with the main component betulin exceeded 10%, since such amounts occur only in the cork of birches with white bark. For the monitoring of purity of the material, subsequently an analysis with respect to aflatoxins, heavy metals, herbicides and pesticides was carried out according to European standards.
- B) Shredded Cork
- The cork was ground in a cutting mill (produced by the company Retsch) and suctioned off out of the machine through a sieve with a pore size of 1 mm diameter. For the further extraction, only particles with a particle size ≦1 mm were employed.
- Extraction of the Triterpene
- For extraction, advantage was taken of the phenomenon that triterpene is practically insoluable from birch cork in cold n-hexane, is however is well soluable in hot n-hexane (140 to 160° C.) under pressure. This process was carried out in two steps:
- 1. The cork was cleansed in a Soxhlett apparatus using a Soxhlett process with n-hexane (hot, <boiling point 69° C.) until the n-hexane solution was no longer yellow.
- 2. The active component or ingredient was extracted from the pre-washed cork granulate with n-hexane at 140 to 160° C. under elevated pressure (extraction by means of Dionex ASE 300 with 100 ml vessels). Upon the quenching of the overheated solution containing n-hexane and triterpene a crystallization occurred immediately, so that a micro-crystalline powder of triterpene was obtained directly in the cold n-hexane. This powder was filtered and washed twice in cold n-hexane. The triterpene was dried at 80 to 100° C.
- Determination of the Purity of the Extract
- The purity of the extract was monitored using gas chromatography (GC). The result is represented in the following diagram.
- Overview: GC of the Extract of Birch Cork with Cholesterol as Internal Standard
-
- The following values were measured:
- Betulin: at least 80%
- Betulinic acid: at most 10%
- Lupeol: at most 3%
- Oleanolic acid: at most 4%
- The overview shows a typical gas chromatogram with values of 84 to 86% betulin, 4 to 5% betulinic acid, approximately 1% lupeol and approximately 1% oleanolic acid.
- According to the requirements of the ICH the amount of the solvent n-hexane remaining must be <7,725 mg/kg extract, while a cream containing 4% birch cork extract may not contain more than 290 mg/kg n-hexane. Typical values comprise 1,500 mg/kg n-hexane in dried extract, which corresponds to approximately 60 mg/kg in the birch cream.
- Final Inspection
- Each charge was checked according to the European requirements with respect to the acid value (<5) and the peroxide number (<15) by means of a standardized process. The content of birch cork extract was analyzed using GC. Further, an examination was made regarding microbes (<100/g); besides this, no pathological microbes may be contained.
- The inventive formulation is set forth in Table 1 (Tab. 1). They were comprised of the following composition:
TAB. 1 Composition of the Formulation Active Component in all Extract from Birch cork Formulations 40 ± 4 mg/g Cream (4%) Formulation Ingredient in % Birch Cream A 29.3 Avocado oil 14.7 Almond oil 52 Water Birch Cream G 29.3 Avocado oil 14.7 Almond oil 5 Glycerin 47 Water Birch Cream H 29.3 Avocado oil 14.7 Almond oil 5 Urea 47 Water - All three formations contained the same amount of the active component (birch cork extract) as well as avocado and almond oil. They differed essentially with respect to the component urea (only in birch cream H) as well as glycerin (only in birch cream G), birch cream A is free of these components.
- Stability Test
- The birch cream was centrifuged at 500×g and was found to be stable therein.
- 1. Acute Toxicity
- The acute toxicity of the birch cork extract was determined by intra-peritoneal and subcutaneous administration to mice and rats.
- Mice
- Individual doses of birch cork extract (charge number: Bet. 001) in Methocel as carrier were subcutaneously administered to five male and five female CD-1 mice. The animals were treated with a dose of 2000 mg/kg based upon their body weight.
- The lethality was determined 14 days after the administration of an individual dose for determination of the average lethal dose LD50. At the same time the animals were observed in order to detect symptoms of toxicity. As such there were considered local and systemic intolerance reactions as well as changes in the body weight. The animals were sacrificed at the end of the experiment and examined microscopically. The acute toxicity test followed EC guidelines L 383 A: B1.
- Under the given test conditions (2000 mg birch cork extract/kg body weight) no intolerance reactions were observed. The animals showed the expected weight gain during the experimental period. The results are assembled in Table 2 (Tab. 2).
TAB. 2 Acute Toxicity in Mice Average body weight during the experimental period Average Body Weight (g) Male Female Beginning 22.8 19.8 Day 7 27.0 22.2 Day 14 31.2 23.6 - In the macroscopic examination changes were observed in three males and three female animals, which could be traced back to the technical examination process employed.
- In this toxicity test the area of the first intolerance reaction, the lowest lethal value as well as the LD50 value lie above 2000 mg birch cork extract/kg body weight.
- Upon intra-peritoneal administration of the birch cork extract in mice toxic symptoms were observed above 500 mg/kg body weight. Only light toxic reactions, such as reduced passive amount of movement, interference in movement coordination and reduced muscle stretch resistance were observed. From this it was concluded, that the toxic symptoms were to be traced back to stomach fur inflammation (peritonitis), which was brought about by the extract solution. A LD50 value could not be determined, so that in the observed time period of 14 days this lie above 200 mg/kg body weight.
- Rats
- Individual doses of birch cork extract (charge number: Bet. 001) in Methocel as carrier were subcutaneously administered to five male and five female Sprague-Dawley rats. The animals were treated with a dose of 2000 mg/kg based upon their body weight.
- The lethality and toxic symptoms were determined 14 days after the administration of an individual dose. The animals were sacrificed at the end of the experiment and examined microscopically. The acute toxicity test followed EC guidelines L 383 A: B1.
- Under the given test conditions (2000 mg birch cork extract/kg body weight) no intolerance reactions or lethality were observed. The animals showed the expected weight gain during the experimental period.
- In the macroscopic examination changes were observed in three males and three female animals, which could be traced back to the technical examination process employed. The results are assembled in Table 3 (Tab. 3).
TAB. 3 Acute Toxicity in Rats Sprague-Dawley Rats (n = 5/sex) Birch cork extract 2000 mg/kg body weight Symptoms/Criteria Male Female Local intolerance reaction none none Systemic intolerance reaction small small Mortality within 6/24 hours none none in 7/14 days Average body weight (g) Beginning 187.6 174.4 Day 7 239.8 203.8 Day 14 280.8 218.0 Loss of body weight none none Macroscopic result 1/5 3/5 - In this toxicity test the range of the first intolerance reaction, the lowest lethal value as well as the LD50 value lie above 2000 mg birch cork extract/kg body weight.
- Upon intraperitoneal administration of the birch cork extract in rats toxic symptoms were observed above 500 mg/kg body weight. Only light toxic reactions, such as reduced passive amount of movement, interference in movement coordination and reduced muscle stretch resistance were observed. From this it was concluded, that the toxic symptoms were to be traced back to stomach fur inflammation (peritonitis), which was brought about by the extract solution. A LD50 value could not be determined, so that in the observed time period of 14 days this lie above 200 mg/kg body weight.
- Further Actions
- The OECD guidelines establish that no further experimentation is necessary, when over a time span of 14 days with an administation of 2000 mg/kg body weight in mice and rats (for each five animals/sex) no mortality resulted from the tested product.
- Chemicals are classified on the basis of their relative toxicity. They are characterized as toxic when the LD50 valve us between 50 and 500 mg/kg body weight. With a LD50 value of 5000 to 15000 mg/kg body weight there is the presumption of practically no toxicity.
- In the present case it has been established that the LD50 value is >2000 mg/kg body weight, and is very likely also >5000 mg/kg body weight, since even with the high value of 2000 mg/kg body weight no toxic symptoms were observed. As can be seen from the experimental results, the birch cork extract can be characterized as non-toxic.
- 2. Subacute Toxicity
- Rats, Intra-peritoneal (i.p.)
- Birch cork extract (charge-number: Bet. 009) was administered to experimental rats (Sprague-Dawley/Crl: CD® BR) by means of intraperitoneal injection over 14 days within the framework of a subacute toxicity test. The test protocol is summarized in Table 4 (Tab. 4).
TAB. 4 Test Protocol of a Subacute Toxicity Test (Rats, i.p.) Animals: 40: (20 male, 20 female) Sprague-Dawley Crl: CD ® BR rats Animal Groups: Group 1-5 5 male/5 female animals in each group Additional 4 (2 male, 2 female) reserve animals, as possible replacements during the acclimation phase Test Protocol*): Birch cork extract (= component of birch cream) Batch number: Bet. 009 Carrier: sesame oil Dose Amount: Group 1: 20 ml carrier/kg body weight/day Group 2: 500 mg/kg body weight/day Group 3: 1000 mg/kg body weight/day Group 4: 2000 mg/kg body weight/day Administration Volume: 20 ml/kg body weight/day Number of Doses: 1 Administration Period: 14 days (day 1-14) Test Period: 15 days (day 1-15) - This subacute toxicity test was used for determining the dose, which was employed in a four week subchronic toxicity test. The results of the toxicity test are shown in Table 5 (Tab. 5).
TAB. 5 Subacute Toxicity Tests in Rats 1 2 3 4 Mortality none none none N = 81) Clinical Result: none in individual2) in all animals greatly animals >Day 13 >Day 10 >Day 7 enlarged abdomen Raw fur none none in all animals >Day 10 >Day 7 Lose in body none in all male animals in both weight >week 1: sexes −18%*) −14%*) >Week 1: End of week 2: −15%*) −15% −12% (male) −12% (female) Change in food none none none reduction intake in test week 1: male: −29% female: −31% Hemotological none none differences to the change (see see (Tab. 6) control group (see Tab. 6) Tab. 6) Changes in none Urea ASAT Urea ASAT Urea ASAT Clinical (see (see Tab. 6) LDH LDH and all Biochemistry Tab. 6) (see Tab. 6) further parameters in the female animals and almost all further parameters in the male animals - The changes in the clinical biochemistry (Tab. 5) are significant relative to the control only in groups 3 and 4 (p≦0.01); in Group 3 with respect to the ASAT activity (+113/+132%), in Group 4 only with female animals with respect to the parameters: total protein, urea in the blood, calcium, potassium and LDH activity.
TAB. 6 Hematological changes in the subacute toxicity test (Rat, i.p.) - definition of Groups 3 and 4 in comparison to Tab. 5 Group 3 changes in % 4 changes in % Parameter male female male female platelet count − +47**) +80 +54**) Reticulocyte − − +64 +36**) count Leukocyte count − − − −34 - The external examination prior to the necroscopic examination showed a significant to heavy enlargement of the abdomen in all groups, with the exception of the control group, in which the abdomen in all animals was only slightly enlarged. The results of the macroscopic post mortem examination is shown in Table 7 (Tab. 7).
TAB. 7 Necroscopic result in the subacute toxicity test - definition of the Groups in comparison to Tab. 4 Group 1 2 3 4 White yellow fluid in + + + + abdominal cavity1) White deposit or layer upon none + + + the diaphragm or upon the abdominal organs Stomach fur inflammation none none none + Abdominal space filled with none none none + white pulp-like/oily approximately content 30 ml - In this two week test for determination of the dose amount, the amount without effect lie at <500 mg birch extract/kg body weight. Significant to strong enlargement of the abdomen was observed at 500 mg/kg body weight and higher. Significant reduction of body weight was observed in all treated groups, however only in the male animals. Coarse or inflamed fur was observed at 1000 mg/kg body weight and higher. Certain hematological and/or biochemical parameters were changed significantly at 1000 mg/kg body weight and higher. The necroscopic examination showed white deposits upon the diaphragm or the abdominal organs, which were partially accompanied by adhesions at 500 mg/kg body weight and higher. In all groups the abdominal cavity was filled with an oily/watery fluid, which could be traced back to the carrier sesame oil. At 2000 mg/kg body weight 8 of 10 animals died. The necroscopic examination showed: 1) stomach fur infection in 4 of the prematurely deceased animals; 2) in all animals the abdominal cavity was filled with pulp-like/oily content. For the subchronic toxicity test an amount of 60 to 540 mg/kg body weight was selected.
- Dogs (Beagle), i.p.
- A subacute toxicity was carried out over a period of two weeks with Beagles as dose-determining experiment, over 4 weeks as subchronic toxicity test. The birch cork extract (Batch No.: Bet. 009) was administered intra-peritoneal with sesame oil as the carrier. The results are summarized in Table 8 (Tab. 8).
TAB. 8 Subacute toxicity test in dogs (Beagle), i.p. Dose amount: 1. MTD*) time 50, 150, 250, 500 mg/kg body weight/day 2. Fixed dose time 100, 300 mg/kg body weight/day Animals: 8 Beagles 2 beagles per sex and group - The results are shown in Table 9 (Tab. 9).
TAB. 9 Subacute toxicity test in dogs (beagles), i.p. No effect: <50 mg/kg body weight/day during the MTD time Lethal dose: 500 mg/kg body weight/day Toxic indication during the fixed dose time: (100, 300 mg/kg body weight/day) Reduced body weight Reduced food uptake Change in hematopoetic and biochemical parameters Heavy stomach fur inflammation in 3 of 8 animals*)
Claims (32)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/748,304 US7482383B2 (en) | 2000-03-28 | 2007-05-14 | Emulsion containing a plant extract, method for producing said emulsion and for obtaining said plant extract |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10015353.4 | 2000-03-28 | ||
DE10015353A DE10015353A1 (en) | 2000-03-28 | 2000-03-28 | Recovery of pure terpenes from plants, for use as pharmaceutical or cosmetic active agents, by extracting with solvent at elevated pressure and temperature then cooling and depressurizing to induce crystallization |
DE10056902A DE10056902A1 (en) | 2000-11-16 | 2000-11-16 | Recovery of pure terpenes from plants, for use as pharmaceutical or cosmetic active agents, by extracting with solvent at elevated pressure and temperature then cooling and depressurizing to induce crystallization |
DE10056902.1 | 2000-11-16 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/748,304 Continuation US7482383B2 (en) | 2000-03-28 | 2007-05-14 | Emulsion containing a plant extract, method for producing said emulsion and for obtaining said plant extract |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030087789A1 true US20030087789A1 (en) | 2003-05-08 |
Family
ID=26005058
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/239,929 Abandoned US20030087789A1 (en) | 2000-03-28 | 2001-03-26 | Emulsion containing a plant extract, method for producing said emulsion and for obtaining a plant extract |
US11/748,304 Expired - Lifetime US7482383B2 (en) | 2000-03-28 | 2007-05-14 | Emulsion containing a plant extract, method for producing said emulsion and for obtaining said plant extract |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/748,304 Expired - Lifetime US7482383B2 (en) | 2000-03-28 | 2007-05-14 | Emulsion containing a plant extract, method for producing said emulsion and for obtaining said plant extract |
Country Status (17)
Country | Link |
---|---|
US (2) | US20030087789A1 (en) |
EP (1) | EP1267900B1 (en) |
JP (1) | JP4593864B2 (en) |
CN (1) | CN100518748C (en) |
AT (1) | ATE264686T1 (en) |
AU (1) | AU2001242517A1 (en) |
CA (1) | CA2404147C (en) |
DE (1) | DE50102055D1 (en) |
DK (1) | DK1267900T3 (en) |
EA (2) | EA013736B1 (en) |
EE (1) | EE04931B1 (en) |
ES (1) | ES2218401T3 (en) |
NO (1) | NO329922B1 (en) |
PL (1) | PL202948B1 (en) |
PT (1) | PT1267900E (en) |
TR (1) | TR200401400T4 (en) |
WO (1) | WO2001072315A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005011717A1 (en) * | 2003-07-03 | 2005-02-10 | Greenpharma S.A. | Use of betulinic acid or an assayed plant extract in betulinic acid individually or associated for cosmetic, neutraceutical, veterinary and pharmaceutical use |
WO2005123037A1 (en) * | 2004-06-22 | 2005-12-29 | Birken Gmbh | Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel |
US20060239957A1 (en) * | 2001-10-03 | 2006-10-26 | Sederma Sas | Cosmetic and dermopharmaceutical compositions for skin prone to acne |
WO2007121352A3 (en) * | 2006-04-13 | 2008-08-28 | Univ Minnesota | Therapeutic triterpenoids |
US20100179219A1 (en) * | 2006-08-17 | 2010-07-15 | Wala-Heilmittel Gmbh | Plane Tree Cream, Method for the Production Thereof and Use |
US20110212218A1 (en) * | 2009-11-04 | 2011-09-01 | Upm-Kymmene Corporation | Method for modulating animal digestive tract microbiota and feed composition comprising bark extract |
US9352041B2 (en) | 2009-11-24 | 2016-05-31 | Birken Ag | Use of an oleogel containing triterpene for healing wounds |
US9468590B2 (en) | 2009-12-10 | 2016-10-18 | Neubourg Skin Care Gmbh & Co. Kg | Emulsifier-free, polymer-stabilized foam formulations |
JP2016210695A (en) * | 2015-04-30 | 2016-12-15 | ポーラ化成工業株式会社 | Skin external preparation |
WO2018017576A1 (en) * | 2016-07-18 | 2018-01-25 | Rolf Daniels | Betulin-containing water-in-oil foams and compositions thereof |
US11083733B2 (en) * | 2018-01-04 | 2021-08-10 | Amryt Research Limited | Betulin-containing birch bark extracts and their formulation |
US11097981B2 (en) | 2016-08-09 | 2021-08-24 | A.L.M. Holding Company | Sterol blends as an additive in asphalt binder |
US11168214B2 (en) | 2016-06-10 | 2021-11-09 | A.L.M. Holding Company | Method for identifying the extent of aging in an asphalt |
US11427697B2 (en) | 2017-07-26 | 2022-08-30 | A.L.M. Holding Company | Use of sterols from animal waste as an additive in asphalt binder |
US11542668B2 (en) | 2017-02-02 | 2023-01-03 | Ergon Asphalt & Emulsions, Inc. | Sterol additive in asphalt pavement |
US11718756B2 (en) | 2017-10-20 | 2023-08-08 | A.L.M. Holding Company | Asphalt emulsion surface treatment containing sterol |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006020582A1 (en) * | 2006-05-03 | 2007-11-15 | Gesellschaft zur Förderung der Krebstherapie e.V. | Process for the preparation of a triterpenic acid-containing aqueous solution, triterpenic acid-containing aqueous solution and their use |
JP2008088109A (en) * | 2006-10-02 | 2008-04-17 | Nitta Gelatin Inc | White birch extract composition and cosmetic comprising white birch formulated therein |
JP2009029734A (en) * | 2007-07-26 | 2009-02-12 | Nippon Menaade Keshohin Kk | External preparation for skin |
FR2949343B1 (en) * | 2009-09-01 | 2011-10-21 | Oreal | PROCESS FOR OBTAINING PLANT EXTRACT, PLANT EXTRACT OBTAINED BY THE METHOD, AND COSMETIC OR DERMATOLOGICAL COMPOSITION CONTAINING THE EXTRACT |
US20220378671A1 (en) * | 2010-03-02 | 2022-12-01 | Neubourg Skin Care Gmbh & Co. Kg | Foam Formulations Containing at Least One Triterpenoid |
PL2363108T3 (en) * | 2010-03-02 | 2018-04-30 | Neubourg Skin Care Gmbh & Co. Kg | Foam formulation containing at least one triterpenoid |
CZ20996U1 (en) * | 2010-05-06 | 2010-06-14 | RNDr. Jan Šarek, Ph.D. - Betulinines | Topic formulation |
DE202011101771U1 (en) | 2011-06-14 | 2011-09-30 | Birken Ag | WASHING AND SEPARATION ASSEMBLY AND A DEVICE WITH A WASHING AND SEPARATING ARRANGEMENT |
KR101723272B1 (en) | 2011-06-21 | 2017-04-18 | 비브이더블유 홀딩 에이쥐 | Medical Device Comprising Boswellic Acid |
KR101304539B1 (en) * | 2011-08-01 | 2013-09-05 | 재단법인 전라남도생물산업진흥재단 | A method for high extraction of oleanolic acid and ursolic acid from Eriobotrya Leaf using supercritical fluid extraction |
WO2017027096A2 (en) | 2015-06-10 | 2017-02-16 | A.L.M Holding Company | Use of sterols as an additive in asphalt binder |
KR102475130B1 (en) * | 2016-03-31 | 2022-12-07 | (주)아모레퍼시픽 | Composition for skin moisturizing or skin whitening comprising pentacyclic triterpene caffeic acid ester |
RU2626914C1 (en) * | 2016-10-17 | 2017-08-02 | Общество с ограниченной ответственностью "КОЛЕТЕКС" | Method for treatment of locally advanced breast cancer with tumour skin ulceration |
CN107049865B (en) * | 2017-04-27 | 2018-03-27 | 养生堂(上海)化妆品研发有限公司 | Skin care cosmetic compositions |
CN107019660B (en) | 2017-04-27 | 2018-05-11 | 养生堂(上海)化妆品研发有限公司 | Moisture-keeping cosmetics composition |
RU2655444C1 (en) * | 2017-09-11 | 2018-05-29 | Акционерное общество "Управляющая компания "Биохимического холдинга "Оргхим" | Method for the isolation of phytosterols from tall pitch |
EP3969003A4 (en) * | 2019-05-15 | 2023-02-08 | Ichilov Tech Ltd. | Method and composition for treatment of skin diseases associated with accelerated corneodesmosomes degradation or weaker cell-cell adhesion |
EP3741378A1 (en) | 2019-05-23 | 2020-11-25 | Dimitrios Tsakouridis | Topical composition for the treatment and care of psoriatic skin |
WO2021011704A1 (en) | 2019-07-15 | 2021-01-21 | A.L.M Holding Company | Sterol in asphalt roofing materials |
CN110664683A (en) * | 2019-10-29 | 2020-01-10 | 广州市博之越精细化工有限公司 | Spot-eliminating formula and application thereof |
SE545843C2 (en) * | 2020-12-23 | 2024-02-20 | Oriflame Cosmetics Ag | Plant extracts for improving skin barrier function |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2764620A (en) * | 1951-12-04 | 1956-09-25 | Phillips Petroleum Co | Adsorption process with heating in downstream end of adsorption column to selectively remove occluded liquids |
US4044031A (en) * | 1976-07-02 | 1977-08-23 | Ake Allan Johansson | Process for the separation of sterols |
US4265824A (en) * | 1978-12-12 | 1981-05-05 | Farmos-Yhtyma Oy | Process for the isolation of β-sitosterol containing a low percentage of α-sitosterol |
US4732708A (en) * | 1985-03-04 | 1988-03-22 | Kemira Oy | Method for converting vegetable material into chemicals |
US5166176A (en) * | 1986-12-29 | 1992-11-24 | Obagi Zein E | Composition for healing damaged skin |
US5466452A (en) * | 1991-02-28 | 1995-11-14 | Phytopharm Ltd. | Pharmaceutical compositions for the treatment of skin disorders |
US5780196A (en) * | 1995-12-27 | 1998-07-14 | Minolta Co., Ltd. | Toner and liquid developer, liquid developer, and method of producing same |
US6175035B1 (en) * | 1997-04-03 | 2001-01-16 | Birgit Draeger | Method of producing betulinic acid |
US6264998B1 (en) * | 2000-03-01 | 2001-07-24 | Dabur Research Foundation | Extracting betulinic acid from Ziziphus jujuba |
US6280778B1 (en) * | 1998-11-02 | 2001-08-28 | Daniel Gaudet | Process for preparing natural product derivatives from plants in a single step |
US6342208B1 (en) * | 1996-08-02 | 2002-01-29 | Plum Kerni Produktion A/S | Oil-in-water emulsion containing C10-C24 fatty acid derivatives for treating skin of mammals |
US6392070B1 (en) * | 1999-08-10 | 2002-05-21 | Regents Of The University Of Minnesota | Birch bark processing and the isolation of natural products from birch bark |
US6682763B2 (en) * | 1999-10-14 | 2004-01-27 | The Nisshin Oil Mills, Ltd. | Skin-beautifying agent, anti-aging agent for the skin, whitening agent and external agent for the skin |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2487356A1 (en) * | 1980-07-25 | 1982-01-29 | Oreal | STABLE EMULSIONS OBTAINED FROM A NATURAL EMULSIFYING AGENT STABILIZED BY ALOE SUCK |
JPS597106A (en) * | 1982-07-06 | 1984-01-14 | Shiseido Co Ltd | Emulsifiable composition |
JPS5967212A (en) * | 1982-10-12 | 1984-04-16 | Kazuo Suga | Comsetic composition |
JPS59206496A (en) * | 1983-05-11 | 1984-11-22 | ライオン株式会社 | Shampoo composition |
JP2652228B2 (en) * | 1988-12-22 | 1997-09-10 | 鐘紡株式会社 | Cosmetics |
DE4318280A1 (en) | 1993-06-02 | 1993-12-16 | Ivo Stane | Compsn. for hair care esp. for treating neuro-dermatitis - contains extract of marigold petals and camomile flowers opt. with other plant extracts in ointment base |
US5843311A (en) | 1994-06-14 | 1998-12-01 | Dionex Corporation | Accelerated solvent extraction method |
US5660727A (en) | 1994-06-14 | 1997-08-26 | Dionex Corporation | Automated analyte supercritical fluid extraction apparatus |
US5647976A (en) | 1995-03-03 | 1997-07-15 | Dionex Corporation | High pressure and temperature cell for solvent extraction |
US6008246A (en) * | 1995-07-12 | 1999-12-28 | Shiseido Co., Ltd. | External preparation for skin containing a low-molecular-weight betaine |
DE19544905A1 (en) | 1995-12-01 | 1997-06-05 | Robugen Gmbh | Preparation of plant extracts |
US5882916A (en) * | 1996-02-15 | 1999-03-16 | Nouveau Technolgies, Inc. | Decontamination process |
JPH10152444A (en) * | 1996-11-22 | 1998-06-09 | Nippon Flour Mills Co Ltd | Inhibitor of maillard reaction and cosmetic |
US6124362A (en) * | 1998-07-17 | 2000-09-26 | The Procter & Gamble Company | Method for regulating hair growth |
-
2001
- 2001-03-26 EA EA200501002A patent/EA013736B1/en not_active IP Right Cessation
- 2001-03-26 US US10/239,929 patent/US20030087789A1/en not_active Abandoned
- 2001-03-26 WO PCT/EP2001/003417 patent/WO2001072315A1/en active IP Right Grant
- 2001-03-26 DE DE50102055T patent/DE50102055D1/en not_active Expired - Lifetime
- 2001-03-26 EE EEP200200552A patent/EE04931B1/en unknown
- 2001-03-26 EA EA200200983A patent/EA006296B1/en not_active IP Right Cessation
- 2001-03-26 AU AU2001242517A patent/AU2001242517A1/en not_active Abandoned
- 2001-03-26 TR TR2004/01400T patent/TR200401400T4/en unknown
- 2001-03-26 PT PT01915417T patent/PT1267900E/en unknown
- 2001-03-26 DK DK01915417T patent/DK1267900T3/en active
- 2001-03-26 AT AT01915417T patent/ATE264686T1/en active
- 2001-03-26 CA CA2404147A patent/CA2404147C/en not_active Expired - Lifetime
- 2001-03-26 EP EP01915417A patent/EP1267900B1/en not_active Expired - Lifetime
- 2001-03-26 CN CNB01808642XA patent/CN100518748C/en not_active Expired - Lifetime
- 2001-03-26 ES ES01915417T patent/ES2218401T3/en not_active Expired - Lifetime
- 2001-03-26 PL PL356723A patent/PL202948B1/en unknown
- 2001-03-26 JP JP2001570276A patent/JP4593864B2/en not_active Expired - Lifetime
-
2002
- 2002-09-25 NO NO20024591A patent/NO329922B1/en not_active IP Right Cessation
-
2007
- 2007-05-14 US US11/748,304 patent/US7482383B2/en not_active Expired - Lifetime
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2764620A (en) * | 1951-12-04 | 1956-09-25 | Phillips Petroleum Co | Adsorption process with heating in downstream end of adsorption column to selectively remove occluded liquids |
US4044031A (en) * | 1976-07-02 | 1977-08-23 | Ake Allan Johansson | Process for the separation of sterols |
US4265824A (en) * | 1978-12-12 | 1981-05-05 | Farmos-Yhtyma Oy | Process for the isolation of β-sitosterol containing a low percentage of α-sitosterol |
US4732708A (en) * | 1985-03-04 | 1988-03-22 | Kemira Oy | Method for converting vegetable material into chemicals |
US5166176A (en) * | 1986-12-29 | 1992-11-24 | Obagi Zein E | Composition for healing damaged skin |
US5466452A (en) * | 1991-02-28 | 1995-11-14 | Phytopharm Ltd. | Pharmaceutical compositions for the treatment of skin disorders |
US5780196A (en) * | 1995-12-27 | 1998-07-14 | Minolta Co., Ltd. | Toner and liquid developer, liquid developer, and method of producing same |
US6342208B1 (en) * | 1996-08-02 | 2002-01-29 | Plum Kerni Produktion A/S | Oil-in-water emulsion containing C10-C24 fatty acid derivatives for treating skin of mammals |
US6175035B1 (en) * | 1997-04-03 | 2001-01-16 | Birgit Draeger | Method of producing betulinic acid |
US6280778B1 (en) * | 1998-11-02 | 2001-08-28 | Daniel Gaudet | Process for preparing natural product derivatives from plants in a single step |
US6392070B1 (en) * | 1999-08-10 | 2002-05-21 | Regents Of The University Of Minnesota | Birch bark processing and the isolation of natural products from birch bark |
US6682763B2 (en) * | 1999-10-14 | 2004-01-27 | The Nisshin Oil Mills, Ltd. | Skin-beautifying agent, anti-aging agent for the skin, whitening agent and external agent for the skin |
US6264998B1 (en) * | 2000-03-01 | 2001-07-24 | Dabur Research Foundation | Extracting betulinic acid from Ziziphus jujuba |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060239957A1 (en) * | 2001-10-03 | 2006-10-26 | Sederma Sas | Cosmetic and dermopharmaceutical compositions for skin prone to acne |
US7182963B2 (en) | 2001-10-03 | 2007-02-27 | Sederma | Cosmetic and dermopharmaceutical compositions for skin prone to acne |
WO2005011717A1 (en) * | 2003-07-03 | 2005-02-10 | Greenpharma S.A. | Use of betulinic acid or an assayed plant extract in betulinic acid individually or associated for cosmetic, neutraceutical, veterinary and pharmaceutical use |
US8536380B2 (en) * | 2004-06-22 | 2013-09-17 | Birken Gmbh | Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel |
WO2005123037A1 (en) * | 2004-06-22 | 2005-12-29 | Birken Gmbh | Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel |
US20070299285A1 (en) * | 2004-06-22 | 2007-12-27 | Scheffler Armin | Triterpene-Containing Oleogel-Forming Agent, Triterpene-Containing Oleogel and Method for Producing a Triterpene-Containing Oleogel |
US8828444B2 (en) * | 2004-06-22 | 2014-09-09 | Birken Ag | Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel |
AU2005253732B2 (en) * | 2004-06-22 | 2009-07-16 | Birken Gmbh | Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel |
AU2005253732C1 (en) * | 2004-06-22 | 2010-01-21 | Birken Gmbh | Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel |
US20090136566A1 (en) * | 2006-04-13 | 2009-05-28 | Regents Of The University Of Minnesota | Therapeutic triterpenoids |
WO2007121352A3 (en) * | 2006-04-13 | 2008-08-28 | Univ Minnesota | Therapeutic triterpenoids |
US20100179219A1 (en) * | 2006-08-17 | 2010-07-15 | Wala-Heilmittel Gmbh | Plane Tree Cream, Method for the Production Thereof and Use |
US20110212218A1 (en) * | 2009-11-04 | 2011-09-01 | Upm-Kymmene Corporation | Method for modulating animal digestive tract microbiota and feed composition comprising bark extract |
US9827214B2 (en) | 2009-11-24 | 2017-11-28 | Amryt Research Limited | Use of an oleogel containing triterpene for healing wounds |
US9352041B2 (en) | 2009-11-24 | 2016-05-31 | Birken Ag | Use of an oleogel containing triterpene for healing wounds |
US9468590B2 (en) | 2009-12-10 | 2016-10-18 | Neubourg Skin Care Gmbh & Co. Kg | Emulsifier-free, polymer-stabilized foam formulations |
JP2016210695A (en) * | 2015-04-30 | 2016-12-15 | ポーラ化成工業株式会社 | Skin external preparation |
US11912874B2 (en) | 2016-06-10 | 2024-02-27 | A.L.M. Holding Company | Crude sterol as an additive in asphalt binder |
US11168214B2 (en) | 2016-06-10 | 2021-11-09 | A.L.M. Holding Company | Method for identifying the extent of aging in an asphalt |
US11760882B2 (en) | 2016-06-10 | 2023-09-19 | A.L.M. Holding Company | Method for identifying the extent of aging in an asphalt |
WO2018017576A1 (en) * | 2016-07-18 | 2018-01-25 | Rolf Daniels | Betulin-containing water-in-oil foams and compositions thereof |
US11667570B2 (en) | 2016-08-09 | 2023-06-06 | A.L.M. Holding Company | Sterol blends as an additive in asphalt binder |
US11097981B2 (en) | 2016-08-09 | 2021-08-24 | A.L.M. Holding Company | Sterol blends as an additive in asphalt binder |
US11542668B2 (en) | 2017-02-02 | 2023-01-03 | Ergon Asphalt & Emulsions, Inc. | Sterol additive in asphalt pavement |
US11427697B2 (en) | 2017-07-26 | 2022-08-30 | A.L.M. Holding Company | Use of sterols from animal waste as an additive in asphalt binder |
US11718756B2 (en) | 2017-10-20 | 2023-08-08 | A.L.M. Holding Company | Asphalt emulsion surface treatment containing sterol |
US12084577B2 (en) | 2017-10-20 | 2024-09-10 | A.L.M. Holding Company | Asphalt emulsion surface treatment containing sterol |
US11266660B2 (en) | 2018-01-04 | 2022-03-08 | Amryt Research Limited | Betulin-containing birch bark extracts and their formulation |
US11826374B2 (en) | 2018-01-04 | 2023-11-28 | Amryt Research Limited | Betulin-containing birch bark extracts and their formulation |
US11083733B2 (en) * | 2018-01-04 | 2021-08-10 | Amryt Research Limited | Betulin-containing birch bark extracts and their formulation |
Also Published As
Publication number | Publication date |
---|---|
AU2001242517A1 (en) | 2001-10-08 |
ES2218401T3 (en) | 2004-11-16 |
TR200401400T4 (en) | 2004-07-21 |
CN1426305A (en) | 2003-06-25 |
NO329922B1 (en) | 2011-01-24 |
DE50102055D1 (en) | 2004-05-27 |
US7482383B2 (en) | 2009-01-27 |
EA200501002A1 (en) | 2006-02-24 |
JP2004519411A (en) | 2004-07-02 |
PT1267900E (en) | 2004-08-31 |
PL202948B1 (en) | 2009-08-31 |
DK1267900T3 (en) | 2004-08-02 |
NO20024591L (en) | 2002-11-11 |
EP1267900B1 (en) | 2004-04-21 |
JP4593864B2 (en) | 2010-12-08 |
CN100518748C (en) | 2009-07-29 |
CA2404147A1 (en) | 2001-10-04 |
NO20024591D0 (en) | 2002-09-25 |
EE200200552A (en) | 2004-04-15 |
EA200200983A1 (en) | 2003-04-24 |
CA2404147C (en) | 2016-07-12 |
EP1267900A1 (en) | 2003-01-02 |
EA006296B1 (en) | 2005-10-27 |
WO2001072315A9 (en) | 2002-10-24 |
ATE264686T1 (en) | 2004-05-15 |
WO2001072315A1 (en) | 2001-10-04 |
US20070231418A1 (en) | 2007-10-04 |
PL356723A1 (en) | 2004-06-28 |
EA013736B1 (en) | 2010-06-30 |
EE04931B1 (en) | 2007-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7482383B2 (en) | Emulsion containing a plant extract, method for producing said emulsion and for obtaining said plant extract | |
JP2768465B2 (en) | Complexes of saponins and phospholipids and pharmaceutical and cosmetic compositions containing them | |
US8535737B2 (en) | Composition with extracts from olive leaf, yarrow and rosemary for treating human diseases and conditions | |
JP3725557B2 (en) | Drugs and cosmetic preparations having anti-acne activity | |
JP4199743B2 (en) | Acne skin cosmetics | |
JP4685374B2 (en) | Topical skin preparation | |
EP0952816B1 (en) | Cosmetic, dermatological and pharmaceutical use of a terminalia catappa extract | |
EP1812029A1 (en) | Composition comprising extract of anemarrhena asphodeloides and aralia elata, and use thereof | |
JPS6236330A (en) | Swertia japonica herba extract and production thereof | |
JP3319870B2 (en) | Skin external composition and bath agent | |
JP4105498B2 (en) | A composition effective for prevention and alleviation of symptoms of atopic disease | |
JPH0386809A (en) | Asparagus saponin-containing cosmetic composition | |
JP3826698B2 (en) | Microbial lipase inhibitor, and acne skin external preparation and dandruff skin external preparation containing the same | |
JP3030706B1 (en) | External preparation for skin and method for producing the same | |
JP2002012550A (en) | Skin care preparation | |
JP3504590B2 (en) | External preparation for skin | |
KR20030092519A (en) | Composition for improving or preventing of allergic dermatological diseases | |
JP2003292451A (en) | Preparation for external use for skin | |
JP2003137798A (en) | Skin care preparation | |
JPH02145504A (en) | External preparation for skin | |
DE10015353A1 (en) | Recovery of pure terpenes from plants, for use as pharmaceutical or cosmetic active agents, by extracting with solvent at elevated pressure and temperature then cooling and depressurizing to induce crystallization | |
JP4883881B2 (en) | External skin preparation for eyes | |
JPS63284110A (en) | Extract of seed of cuscuta japonica choisy | |
JPH10194916A (en) | Antimicrobial and low-irritating cosmetic | |
JP2003292416A (en) | Skin care preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BIRKEN GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SCHEFFLER, ARMIN;REEL/FRAME:013761/0392 Effective date: 20020918 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: BIRKEN AG, GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:BIRKEN GMBH;REEL/FRAME:037132/0051 Effective date: 20110323 |
|
AS | Assignment |
Owner name: AMRYT RESEARCH LIMITED, IRELAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIRKEN AG;REEL/FRAME:038700/0466 Effective date: 20160524 |
|
AS | Assignment |
Owner name: AMRYT PHARMACEUTICALS DESIGNATED ACTIVITY COMPANY, IRELAND Free format text: MERGER;ASSIGNOR:AMRYT RESEARCH LIMITED;REEL/FRAME:066110/0568 Effective date: 20231218 |